Divalproex Sodium
Product Images NDC 16590-648

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 16590-648). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sod Dr 500mg Label Image (Divalproex Sod Dr 500mg Label)

Packaging label for DIVALPROEX SODIUM DR 500 mg delayed-release tablets. The label shows a quantity of 30 tablets in the package. It is labeled by STAT RX USA LLC and notes the product is generic for Depakote. The label includes storage instructions and warnings about CNS and alcohol use. The NDC number 16590-648-30 is displayed prominently.*

FDA Label Image

Divalproex-na-fig1 (Divalproex Na Fig1)

A bar chart compares the percentage results of two studies labeled as Study 1 (YMRS) and Study 2 (MRS) for Placebo (PBO) and Divalproex sodium delayed-release tablets (DVPX). Study 1 shows 26% for Placebo and 60% for DVPX, while Study 2 shows 29% for Placebo and 58% for DVPX. An asterisk indicates significance with p < 0.05.*

FDA Label Image

Divalproex-na-fig2 (Divalproex Na Fig2)

A bar chart comparing the effect of placebo versus divalproex sodium delayed-release tablets (DVPX) in two studies. The vertical axis is labeled from 0 to 6, showing lower values for DVPX groups compared to placebo in both studies. Below the chart are notes describing the mean doses used in each study, with DVPX doses at 1087 mg/day in Study 1 and 500 or 1000 mg/day in Study 2.*

FDA Label Image

Divalproex-na-fig3 (Divalproex Na Fig3)

A cumulative response curve graph comparing Divalproex sodium delayed-release tablets (DVPX) and placebo in terms of percent reduction in CPS rate among patients. The vertical axis shows percent reduction in CPS rate from -100% to 100%, and the horizontal axis shows percent of patients from 100% to 0%. The graph indicates improvement and worsening trends for both DVPX and placebo groups.*

FDA Label Image

Divalproex-na-fig4 (Divalproex Na Fig4)

A line graph showing the percentage reduction in CPS rate versus the percentage of patients, comparing high dose and low dose groups. The vertical axis indicates improvement or worsening, while the horizontal axis shows the percentage of patients, illustrating the treatment effect of DIVALPROEX SODIUM DR.*

FDA Label Image

Divalproex-na-structure (Divalproex Na Structure)

Chemical structure of divalproex sodium showing the repeating unit of the molecule with sodium ion and carboxylate groups represented in the polymer structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.